Marketed in 61 countries across Europe, the Americas, the Middle East, and the Asia-Pacific region, Crestor is a globally distributed brand of rosuvastatin, classified within the lipid-modifying class of medications that work by inhibiting HMG-CoA reductase. Its broad regulatory footprint means travellers and expatriates routinely encounter it abroad — sometimes under the Crestor name, sometimes as a rosuvastatin generic.
Rosuvastatin is prescribed in the management of elevated cholesterol and related lipid disorders, and is used as part of the broader prevention strategy for cardiovascular conditions including coronary heart disease, heart attack, and cerebrovascular events. It also appears in treatment plans that address overall cardiovascular risk in patients with hypertension or a history of smoking. The structured indication block further down this page lists each registered use as recognised in the markets where Crestor is sold.
Because Crestor circulates so widely, the practical question for an international reader is usually about continuity rather than discovery. Markets where the brand is registered include Australia, Canada, China, Egypt, and Chile, but packaging, prescription pathways, and the availability of generic rosuvastatin differ substantially from one regulatory regime to another. A pharmacist in the destination country can confirm whether a locally stocked rosuvastatin product corresponds to the Crestor a patient was using at home.
Other molecules in the lipid-modifying class — and specifically other HMG-CoA reductase inhibitors — are sold in many of the same markets under various brand names, though they are not freely interchangeable with rosuvastatin. Any decision to start, stop, or switch a lipid-lowering medication belongs with a healthcare provider who knows the patient's full cardiovascular picture.
